Jefferies downgraded Icosavax (ICVX) to Hold from Buy with a price target of $15.50, down from $30, after the company agreed to be acquired by AstraZeneca (AZN) for $15.00 per share in cash at closing plus a non-tradable contingent value right to receive up to $5.00 in cash.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ICVX: